跳至主要内容
临床试验/NCT02662842
NCT02662842已完成不适用

BD FlowSmart™ User Claims Study

Becton, Dickinson and Company4 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2016年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
75
试验地点
4
主要终点
Comparative Infusion Set Wear Comfort

研究概览

简要总结

Continuous Subcutaneous Insulin Infusion (CSII) via insulin pump therapy has been shown to improve quality of life and glucose control in many patients with diabetes opting for this treatment modality. Despite significant innovation and advancement in pump technology, insulin infusion sets have been an area where innovation has been significantly lacking with no clinical studies performed prior to product launches.

BD has developed a subcutaneous infusion set with FlowSmart™ Technology designed to address patient comfort, insulin delivery and flow interruptions. According to preliminary animal and clinical studies, this technology results in lower infusion pressure indicating more consistent insulin delivery.

The FlowSmart infusion set has been previously tested in prototype form with healthy non-diabetic subjects with the sets inserted by nurses, and with CSII-using patients who self-inserted the FlowSmart infusion set in a clinical research setting.

The purpose of this study is to determine if insulin pump users prefer using the BD FlowSmart infusion set compared to their current set with respect to insertion pain and wear comfort.

研究设计

研究类型
Observational
观察模型
Case Crossover
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Must be 18-75 years of age, inclusive
  • Have type 1 diabetes
  • Treating diabetes with CSII for at least 12 months
  • Currently using a soft catheter infusion set that is inserted 90° to body surface
  • Have HbA1c ≤ 9.0% (tested at enrollment)
  • Willing to do self monitoring of blood glucose (SMBG) using the supplied BG meter
  • Able to read, write and follow instructions in English
  • Able and willing to provide informed consent
  • Willing to use each infusion set (both study and current) for 72 hours (3 days)
  • Willing to use their usual insertion method (manual or mechanical inserter) with both infusion sets

排除标准

  • Pregnant (pre-menopausal females only; tested at enrollment)
  • Recent history (within 6 months) of unstable diabetes including ketoacidosis, hyperglycemia and/or hypoglycemia requiring hospitalization(self-reported)
  • Physical conditions that restrict dexterity and may limit ability to perform study procedure (e.g., severe neuropathy or arthritis of the hands, self-reported)
  • Any other condition the PI or designee deems to pose a risk to the subject in the study
  • Currently taking steroidal medications (self-reported)
  • Acutely ill as determined by the Principal Investigator.
  • Currently using an insulin infusion pump whose insulin reservoir is not compatible with either a Paradigm or Luer connector, such as Sooil Dana, Asante Snap, and Accu-Chek insight
  • Currently using a disposable (patch) insulin pump, such as the Insulet Omnipod and the Valeritas V-Go
  • Currently using a Teflon infusion set that is not inserted at a 90° angle, such as the Animas Comfort, Animas Inset 30, Medtronic Silhouette, or a steel infusion set, such as the Accu-Chek Rapid-D or Medtronic Sure-T
  • Currently using Advanced Diabetes Research (ADR) reservoirs
  • Currently participating in any other clinical investigations that conflicts with this one, or who have participated in a study with the same indication within the last 3 months and that the Principal Investigator or designee believes will conflict with outcomes or ability of the subject to complete all activities required in the study
  • Participated in one or more of the following BD studies: DBC-14SCARL10 and DBC-14SCARL13
  • Employed by, or currently serving as a contractor or consultant to BD or study site

结局指标

主要结局

Comparative Infusion Set Wear Comfort

时间窗: Comparative pain measure assessed at the end of Study Period 2, after 9-11 days use of each infusion set type

At the study visit after completing both study periods (Visit 3), subjects will use a 15 cm Visual Analog Scale (VAS) to indicate which set was more comfortable to wear, the BD FlowSmart or their current infusion set. Only if reduced Pain (outcome 1) for FlowSmart if achieved will wear comfort be further analyzed. Effects of infusion set type will be tested for statistical significance using linear mixed models adjusting for the effect of subject, study site and period. The model will be used to generate a two-sided 95% confidence interval for the adjusted average comfort rating using a multiple comparison approach.

Comparative Infusion Set Insertion Pain

时间窗: Comparative pain measure assessed at the end of Study Period 2, after 9-11 days use of each infusion set type

At the study visit after completing both study periods (Visit 3), subjects will use a 15 cm Visual Analog Scale (VAS) to indicate which insertion set was less painful to insert, the BD Flowsmart or their current infusion set. Effects of infusion set type will be tested for statistical significance using linear mixed models adjusting for the effect of subject, study site and period. The model will be used to generate a two-sided 95% confidence interval for the adjusted average pain rating using a multiple comparison approach.

次要结局

  • Overall Infusion Set Preference(Assessed at the end of Study Period 2, after 9-11 days use of each infusion set type)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验